scholarly journals Postmenopausal hormone therapy and ductal carcinoma in situ: A population-based case–control study

2012 ◽  
Vol 36 (2) ◽  
pp. 161-168 ◽  
Author(s):  
Lisa Calvocoressi ◽  
Meredith H. Stowe ◽  
Darryl Carter ◽  
Elizabeth B. Claus
Keyword(s):  
Hormone Therapy ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Case Control Study ◽  
Ductal Carcinoma ◽  
Population Based ◽  
Case Control ◽  
Postmenopausal Hormone Therapy ◽  
Control Study

scholarly journals Postmenopausal hormone therapy and the risk of rheumatoid arthritis: results from the Swedish EIRA population-based case-control study

2015 ◽  
Vol 30 (5) ◽  
pp. 449-457 ◽  
Author(s):  
Cecilia Orellana ◽  
Saedis Saevarsdottir ◽  
Lars Klareskog ◽  
Elizabeth W. Karlson ◽  
Lars Alfredsson ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Hormone Therapy ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Postmenopausal Hormone Therapy ◽  
Postmenopausal Hormone ◽  
Control Study

scholarly journals Smoking, postmenopausal hormone therapy and the risk of venous thrombosis: a population-based, case-control study

2013 ◽  
Vol 163 (3) ◽  
pp. 418-420 ◽  
Author(s):  
Marc Blondon ◽  
Kerri L. Wiggins ◽  
Astrid Van Hylckama Vlieg ◽  
Barbara McKnight ◽  
Bruce M. Psaty ◽  
...  
Keyword(s):  
Venous Thrombosis ◽  
Hormone Therapy ◽  
Case Control Study ◽  
Population Based ◽  
Case Control ◽  
Postmenopausal Hormone Therapy ◽  
Postmenopausal Hormone ◽  
Control Study

scholarly journals Clinicopathological Risk Factors for an Invasive Breast Cancer Recurrence after Ductal Carcinoma In Situ—A Nested Case–Control Study

2018 ◽  
Vol 24 (15) ◽  
pp. 3593-3601 ◽  
Author(s):  
Lindy L. Visser ◽  
Lotte E. Elshof ◽  
Michael Schaapveld ◽  
Koen van de Vijver ◽  
Emma J. Groen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Risk Factors ◽  
Carcinoma In Situ ◽  
Case Control Study ◽  
Ductal Carcinoma ◽  
Cancer Recurrence ◽  
Case Control ◽  
Nested Case Control ◽  
Control Study

scholarly journals Difficulties in collecting data on ductal carcinoma in situ at a Population-based Cancer Registry

Mastology ◽  
2019 ◽  
Vol 29 (2) ◽  
pp. 86-89
Author(s):  
Nayara Alves de Freitas Lemos ◽  
◽  
Ruffo Freitas- Junior ◽  
Marise Amaral Rebouças Moreira ◽  
Thaysa Cardoso Silva ◽  
...  
Keyword(s):  
Cancer Registry ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Population Based

scholarly journals Prescribing practices of endocrine therapy for ductal carcinoma in situ in British Columbia

2018 ◽  
Vol 25 (2) ◽  
pp. 133 ◽  
Author(s):  
A.T. Chaudhry ◽  
T.A. Koulis ◽  
C. Speers ◽  
R.A. Olson
Keyword(s):  
British Columbia ◽  
Endocrine Therapy ◽  
Ductal Carcinoma In Situ ◽  
Carcinoma In Situ ◽  
Ductal Carcinoma ◽  
Population Based ◽  
Cox Regression Analysis ◽  
Treatment Centre ◽  
Er Status

Purpose The mainstay of treatment for ductal carcinoma in situ (dcis) involves surgery in the form of mastectomy or lumpectomy. Inconsistency in the use of endocrine therapy (et) for dcis is evident worldwide. We sought to assess the variation in et prescribing for patients with dcis across a population-based radiotherapy (rt) program and to identify variables that predict its use.Methods Data from a breast cancer database were obtained for women diagnosed with dcis in British Columbia from 2009 to 2014. Associations between et use and patient characteristics were assessed by chi-square test and multilevel multivariate logistic regression. The Kaplan–Meier method, with propensity score matching and Cox regression analysis, was used to assess the effects of et on overall survival (os) and relapse-free survival (rfs).Results For the 2336 dcis patients included in the study, et use was 13% in dcis patients overall, and 17% in patients with estrogen receptor–positive (er+) tumours treated with breast-conserving surgery and rt. Significant variation in et use by treatment centre was observed (range: 8%–23%; p < 0.001), and prescription of et by individual oncologists varied in the range 0%–40%. After controlling for confounding factors, age less than 50 years [odds ratio (or): 1.72; p = 0.01], treatment centre, er+ status (or: 5.33; p < 0.001), and rt use (or: 1.77; p < 0.001) were significant predictors of et use. No difference in os or rfs with the use of et was observed.Conclusions In this population-based analysis, 13% of patients with dcis in British Columbia received et, with variation by treatment centre (8%–23%) and individual oncologist (0%–40%). Age less than 50 years, er+ status, and rt use were most associated with et use.

Sign in / Sign up

Export Citation Format

Share Document